GlassScriptPhysician profile
Anar Patel
NPI 1801152251
$3,091.65
in general payments reported to CMS, 2019-2025
18 companies · $1,564 in 2025
The $1,564 reported for 2025 was more than what 83% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $360 · 2024: $1,168 · 2025: $1,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,091.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $754.10 | 2023-2025 | Cabenuva, Dovato, Apretude |
| Gilead Sciences, INC. | $514.09 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $431.86 | 2024-2025 | Pifeltro, Delstrigo, Zerbaxa |
| Abbvie INC. | $380.15 | 2023-2025 | |
| Melinta Therapeutics, LLC | $202.95 | 2023-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Paratek Pharmaceuticals, INC. | $189.09 | 2024-2025 | Nuzyra |
| Insmed, INC. | $159.17 | 2024-2025 | Arikayce, Brinsupri |
| Astellas Pharma US INC | $113.45 | 2023-2024 | Cresemba |
| Aimmune Therapeutics, INC. | $100.02 | 2024-2025 | Vowst |
| Emd Serono, INC. | $69.65 | 2025 | |
| La Jolla Pharmaceutical Company | $35.32 | 2025 | Zevtera |
| Shionogi INC | $25.58 | 2025 | Fetroja |
| Pfizer INC. | $23.63 | 2023 | |
| Philips North America LLC | $22.59 | 2025 | Lm Accessories |
| Dexcom, INC. | $21.88 | 2025 | Dexcom G6 Transmitter |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $19.09 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $14.66 | 2025 | Vibativ |
| Tetraphase Pharmaceuticals, INC. | $14.37 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.